生物制药公司Atai Beckley Inc今日盘中股价大幅上涨5.01%，引起了市场关注。
消息面上，公司宣布其针对耐药性抑郁症的实验性药物BPL-003在获得美国食品药品监督管理局（FDA）的积极反馈后，计划于2026年第二季度进入三期临床试验阶段。该药物为鼻腔喷雾剂，在中期研究中显示出快速起效（两天内）且疗效持久（可达八周）的特点，主要针对现有疗法无效的严重抑郁症患者。
此外，Atai Beckley在近日的投资者日活动上重点介绍了其研发管线的多项关键里程碑，并重申公司现金流预计可持续至2029年初。这些积极的研发进展和稳健的财务前景，增强了投资者对公司未来增长潜力的信心，从而推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.